Most people with multiple sclerosis (MS) have a type called relapsing-remitting MS (RRMS ... to a different type of MS called secondary progressive multiple sclerosis. You won’t have relapses ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis ... MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

EDSS score‡ 5.5±1.0 5.6±0.9 Time since onset of symptoms of relapsing–remitting multiple sclerosis — yr 17.1±8.3 17.6±8.4 Time since diagnosis of secondary progressive multiple sclerosis ...

The following is a summary of “Secondary progression activity monitoring in MS despite an early highly active treatment the ...

SAN DIEGO — Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis ...

Multiple sclerosis (MS) treatment could be on ... There's no drug approved for non-relapsing secondary progressive MS, and those patients really deserve also a treatment. So, what can we do?

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England ...

New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in multiple ... trial in non-relapsing secondary progressive MS. Primary ...